Sandoz announced that its denosumab biosimilar, Jubbonti and Wyost, received marketing authorization from Health Canada on 20 February and 4 March 2024, respectively. Subsequently, on 5 March 2024, the company announced that the US Food and Drug Administration (FDA) approved the two biosimilar denosumab denosumab-bddz, Jubbonti and Wyost, for all indications of the reference medicines, Amgen’s Prolia and Xgeva. These are the first and only denosumab biosimilars for osteoporosis and increasing bone mass approved in Canada and the US.

Denosumab is a humanized monoclonal antibody that is an inhibitor of the receptor activator of nuclear factor kappa-B ligand (RANKL), which works by preventing the development of osteoclasts which are cells that break down bone. It is used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumour of bone [1].

The originator product is Amgen’s Prolia/Xgeva (denosumab). This is marketed as Prolia for the treatment of osteoporosis. A different dose of the antibody is marketed as Xgeva for preventing bone problems in multiple myeloma patients and those whose solid tumours have metastasized to the bones.

FDA approved Jubbonti injection as an interchangeable biosimilar to US-licensed Prolia, and Wyost injection as an interchangeable biosimilar to US-licensed Xgeva. The approval for Jubbonti and Wyost is the same for Health Canada, with the exception that it does not have the distinction of an interchangeable biosimilar as in the US.

Health Canada approval based on phase I and phase III clinical studies. The FDA approval is based on clinical studies and accompanied by labelling with safety warnings. The Jubbonti approval is also accompanied by approval of Sandoz’s Jubbonti Risk Evaluation and Mitigation Strategy (REMS) programme.

In Canada and the US, Jubbonti will be available as a 60 mg/mL solution in single-use pre-filled syringe for subcutaneous injection, and Wyost will be available in 120 mg/1.7 mL (70 mg/mL) solution delivered as a subcutaneous injection every four weeks. 

Jubbonti is approved for the osteoporosis indication and Wyost is approved for the prevention of bone-related complications from cancer,

Jubbonti and Wyost marks Sandoz Canada's eighth approved biosimilars, while Sandoz US has a total of seven biosimilars approved. For a comprehensive overview of Sandoz's biosimilars approved in both Canada and the US, please refer to Table 1 [2, 3].

Related articles
Sandoz to start phase III trial for denosumab biosimilar

Denosumab biosimilar being developed in Australia

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of denosumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Apr 3]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-denosumab
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Apr 3]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Canada
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Apr 3]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.